In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsInvasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literatureIn vitro activity of A-192411.29, a novel antifungal lipopeptideAn Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits Candida albicans and Mixed C. albicans - Staphyloccoccus aureus BiofilmsSafety and pharmacokinetics of repeat-dose micafungin in young infants.Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.Peptide-based Antifungal Therapies against Emerging Infections.Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Micafungin.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsNew investigational antifungal agents for treating invasive fungal infections.Antifungal pharmacodynamics: review of the literature and clinical applications.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studiesInvestigational antifungal agents.Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibilityEfficacy of micafungin alone or in combination against systemic murine aspergillosis.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisInfections caused by Fusarium species.New and emerging antifungal agents: impact on respiratory infections.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsAltered Micafungin Pharmacokinetics in Intensive Care Unit PatientsMicafungin: pharmacology, experimental therapeutics and clinical applications.Micafungin: the US perspective.Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosisDevelopments in the treatment of candidiasis: more choices and new challenges.Micafungin: a new echinocandin antifungal.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.Micafungin for the prophylaxis and treatment of Candida infections.
P2860
Q27025299-19592B68-BF1C-4969-B9A4-7F38D3026D69Q28243864-42A6FF32-0C30-4DC5-9C40-B7C48273B19AQ28344147-80C605BF-DD53-469C-A271-7A2105DA2398Q28552679-8F478121-AAD0-4663-8E5C-06E3FED4BE17Q30433612-999CBC26-1ED0-47A6-981C-B92E7EC9B3F5Q33722115-BC8B312E-E912-406A-A742-AB493DFF91A6Q33826372-E83C2A11-05BE-4540-8B86-6D876DCA3879Q33862289-E508BC9C-8997-4C63-B2F1-C932EA02BD80Q33938201-6F3F5728-6E03-45C4-AE6E-6ED2D50D725DQ33980368-4D646F7B-9ECD-4088-8C4C-A16410F3EDF2Q33981019-92F9858D-FB07-4E78-8F7F-2F62364F3574Q33983499-07BC9714-3F31-45F6-A18E-DA9866846675Q33983506-F547C417-4323-49C2-A55C-65B30EC509D1Q34006585-67A00F3F-0406-49CF-BDDB-B274FD8263E3Q34045450-5E7BF558-FD39-4332-B3F5-D0DB6C913503Q34075014-2ACE920B-D2C1-4FA3-8036-F0A21AA3E618Q34083129-1D39F177-012C-4E4D-B3C9-342F4A7B829AQ34108880-94BB048A-830B-4BD5-8999-8BBD5FB4542AQ34253266-8065B2D4-5FBD-4943-8521-A04FC80D2D89Q34335243-F9C4DCDC-F152-4DCA-84C9-A16BA6A1DD6BQ34510707-503E455D-4F42-4A16-9DFC-9A69F64881A7Q34884594-E042E085-0C8A-41FE-BBB2-5ED87E438DE7Q35026516-1536860E-FF97-4251-9FEE-9BE61A27884CQ35622021-89716312-089F-4713-870D-A738271681DFQ35627629-462D0FE5-84F2-4FAE-A23D-0713B6FB2399Q35635928-F7AB14CE-669C-4A8F-8405-460C96031897Q35860004-1ACAB645-D30B-4D06-A05A-7B46C0F01B65Q36120798-338DCC02-9FEE-41F8-8E67-6219DD86FC1FQ36140652-A06ACA69-48D7-4BC0-9F39-37FCBADD82B2Q36424929-71B1B0CE-0713-4D23-8185-AC2A341A5EAEQ36441524-2951772E-663F-4800-9E63-BDAF1868ECA7Q36458402-930DD318-8598-4B59-8F02-9D3C12C534D9Q36491819-149A7AF1-AD97-43B9-8E37-F5FCC9330180Q36593863-41E16A58-29E8-46B6-BF8D-458E202E0D58Q36623050-E2C1C96B-DBCB-4CAF-AED0-A58101167ED9Q36693843-F0556768-87FC-41DE-AA50-1EEA7F527937Q36828156-6F2FFD2E-7A58-4122-AFE6-B4EDBE161857Q36867925-2CB7CF51-C68C-40FD-9B17-C32C4511ABF7Q36895679-5BC19226-7836-4BCC-9D31-B75BA3C9B2BBQ37124868-5AD408F5-F9A1-4190-882C-2E033571CA86
P2860
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro activities of a new l ...... of clinically important fungi
@ast
In vitro activities of a new l ...... of clinically important fungi
@en
In vitro activities of a new l ...... of clinically important fungi
@nl
type
label
In vitro activities of a new l ...... of clinically important fungi
@ast
In vitro activities of a new l ...... of clinically important fungi
@en
In vitro activities of a new l ...... of clinically important fungi
@nl
prefLabel
In vitro activities of a new l ...... of clinically important fungi
@ast
In vitro activities of a new l ...... of clinically important fungi
@en
In vitro activities of a new l ...... of clinically important fungi
@nl
P2093
P2860
P3181
P1476
In vitro activities of a new l ...... of clinically important fungi
@en
P2093
F Matsumoto
H Takasugi
K Kawabata
P2860
P3181
P356
10.1128/AAC.44.1.57-62.2000
P407
P577
2000-01-01T00:00:00Z